timothy sykes logo
SCNI Stock Wobbles As Scinai Refocuses On NanoAb Platform Thumbnail
G Google News

SCNI Stock Wobbles As Scinai Refocuses On NanoAb Platform

JACK KELLOGG•UPDATED SEP. 21, 2026, 7:48 AM ET
Reviewed by Tim Sykesand Fact-checked by Ellis Hobbs

Scinai Immunotherapeutics Ltd. stocks have been trading up by 14.06 percent amid heightened optimism from its latest biotech developments

Key Takeaways

  • Scinai Immunotherapeutics is terminating its option and license agreements with PinCell for PC111, exiting that partnered dermatology program.
  • The company is reallocating R&D capital toward its in-house NanoAb antibody platform, signaling a bet on proprietary science.
  • Management is emphasizing growth of its CDMO arm, Scinai Biopharma Services, as a service-revenue engine.
  • Scinai is continuing its collaboration with the Max Planck Society and University Medical Center Göttingen, keeping core research partnerships intact.

Candlestick Chart

Live Update At 07:47:43 EDT: On Monday, September 21, 2026 Scinai Immunotherapeutics Ltd. stock [NASDAQ: SCNI] is trending up by 14.06%! Discover the key drivers behind this movement as well as our expert analysis in the detailed breakdown below.

Quick Financial Overview

SCNI has been trading like a small-cap biotech battleground. Over the past few weeks, Scinai Immunotherapeutics shares slid from the $2.60s down into the mid‑$1.50s. That’s a sharp reset and tells traders the market is still uncertain about the company’s path. The recent trading range between roughly $1.50 and $1.80 shows SCNI trying to build a new base after that selloff.

Intraday, SCNI has flashed serious volatility. A premarket ramp from about $1.60 to above $2.15 in minutes, followed by a fade back under $1.85, highlights exactly the kind of wild action short‑term traders look for. Big wicks, fast reversals, and expanding ranges point to active day trading rather than quiet accumulation.

More Breaking News

On the fundamentals, Scinai Immunotherapeutics is tiny. Revenue is about $1.31M, and the enterprise value sits near $7.02M, implying the market is giving SCNI a low price-to-sales multiple of around 0.6. Book value per share is reported at 4.94, so the stock trades at a steep discount to its stated equity. At the same time, return on equity and return on assets are deeply negative, reminding traders this is still an early-stage, loss‑making biotech trying to prove its model.

Why Traders Are Watching SCNI’s Strategic Pivot

The latest headline move from Scinai Immunotherapeutics is all about focus. SCNI is walking away from its option and license agreements with PinCell for PC111, a partnered dermatology asset, and redirecting that R&D firepower into its own NanoAb antibody platform. For traders, that’s a clear signal: Scinai wants to control more of its destiny.

When a small biotech like SCNI ditches a partnered program, it usually sparks knee‑jerk fear that “something went wrong.” But in this case, Scinai Immunotherapeutics is pairing the exit with a pivot toward higher‑potential in‑house technology. The NanoAb platform is where SCNI believes it can build real long‑term value, instead of sharing upside on PC111.

At the same time, Scinai is leaning hard into its CDMO unit, Scinai Biopharma Services. That business offers contract development and manufacturing services, which tend to generate steadier, service-based revenue compared to binary drug readouts. For traders, this adds a second leg to the story: SCNI as both a platform biotech and a niche biomanufacturing player.

The ongoing collaboration with the Max Planck Society and University Medical Center Göttingen gives the NanoAb story scientific backing. SCNI is not walking away from innovation; it is concentrating it. The trade‑off is execution risk. If the NanoAb platform or CDMO push stalls, the loss of the PC111 option will sting. That tension is exactly what fuels the volatility we see on the SCNI tape.

Conclusion

SCNI sits at an important crossroads. The chart shows a name that ran, broke down from the $2.50–$2.70 zone, and is now trying to hold the mid‑$1s while traders digest Scinai Immunotherapeutics’ strategic reset. Cheap valuation metrics look attractive on paper, but negative returns on capital remind everyone that Scinai still has a lot to prove.

The decision to terminate the PinCell PC111 agreements and move R&D capital into the NanoAb antibody platform is a classic “cut what’s non‑core, double down on your edge” move. For active traders, that means the next big catalysts for SCNI are likely to come from NanoAb updates and new CDMO contracts at Scinai Biopharma Services, not from legacy partnered assets.

Risk remains high. SCNI is a thin, volatile biotech with limited revenue, a small balance sheet, and heavy dependence on successful execution of its refocused strategy. But that’s exactly the type of stock that can deliver sharp, tradeable swings when headlines hit. As millionaire penny stock trader and teacher Tim Sykes, says, “Be patient, don’t force trades, and let the perfect setups come to you.” That mindset is especially relevant with a volatile ticker like SCNI, where waiting for clean news‑driven setups and clear technical levels can make the difference between a disciplined trade and a costly chase.

Tim Sykes puts it simply: “The market rewards preparation, not hope. Study the news, study the chart, and always know your exit before you enter.” For anyone tracking Scinai Immunotherapeutics, that means watching how price reacts around key support in the $1.50 area, tracking volume on every NanoAb and CDMO headline, and treating SCNI as a trading vehicle for educational and research purposes — never as a blind long‑term bet.

This is stock news, not investment advice. Timothy Sykes News delivers real-time stock market news focused on key catalysts driving short-term price movements. Our content is tailored for active traders and investors seeking to capitalize on rapid price fluctuations, particularly in volatile sectors like penny stocks. Readers come to us for detailed coverage on earnings reports, mergers, FDA approvals, new contracts, and unusual trading volumes that can trigger significant short-term price action. Some users utilize our news to explain sudden stock movements, while others rely on it for diligent research into potential investment opportunities.

Dive deeper into the world of trading with Timothy Sykes, renowned for his expertise in penny stocks. Explore his top picks and discover the strategies that have propelled him to success with these articles:

Once you’ve got some stocks on watch, elevate your trading game with StocksToTrade the ultimate platform for traders. With specialized tools for swing and day trading, StocksToTrade will guide you through the market’s twists and turns.
Dig into StocksToTrade’s watchlists here:

How much has this post helped you?

(0 votes, average: 0 out of 5)
Leave a reply

* Results are not typical and will vary from person to person. Making money trading stocks takes time, dedication, and hard work. There are inherent risks involved with investing in the stock market, including the loss of your investment. Past performance in the market is not indicative of future results. Any investment is at your own risk. See Terms of Service here

The available research on day trading suggests that most active traders lose money. Fees and overtrading are major contributors to these losses.

A 2000 study called “Trading is Hazardous to Your Wealth: The Common Stock Investment Performance of Individual Investors” evaluated 66,465 U.S. households that held stocks from 1991 to 1996. The households that traded most averaged an 11.4% annual return during a period where the overall market gained 17.9%. These lower returns were attributed to overconfidence.

A 2014 paper (revised 2019) titled “Learning Fast or Slow?” analyzed the complete transaction history of the Taiwan Stock Exchange between 1992 and 2006. It looked at the ongoing performance of day traders in this sample, and found that 97% of day traders can expect to lose money from trading, and more than 90% of all day trading volume can be traced to investors who predictably lose money. Additionally, it tied the behavior of gamblers and drivers who get more speeding tickets to overtrading, and cited studies showing that legalized gambling has an inverse effect on trading volume.

A 2019 research study (revised 2020) called “Day Trading for a Living?” observed 19,646 Brazilian futures contract traders who started day trading from 2013 to 2015, and recorded two years of their trading activity. The study authors found that 97% of traders with more than 300 days actively trading lost money, and only 1.1% earned more than the Brazilian minimum wage ($16 USD per day). They hypothesized that the greater returns shown in previous studies did not differentiate between frequent day traders and those who traded rarely, and that more frequent trading activity decreases the chance of profitability.

These studies show the wide variance of the available data on day trading profitability. One thing that seems clear from the research is that most day traders lose money .

Millionaire Media 66 W Flagler St. Ste. 900 Miami, FL 33130 United States (888) 878-3621 This is for information purposes only as Millionaire Media LLC nor Timothy Sykes is registered as a securities broker-dealer or an investment adviser. No information herein is intended as securities brokerage, investment, tax, accounting or legal advice, as an offer or solicitation of an offer to sell or buy, or as an endorsement, recommendation or sponsorship of any company, security or fund. Millionaire Media LLC and Timothy Sykes cannot and does not assess, verify or guarantee the adequacy, accuracy or completeness of any information, the suitability or profitability of any particular investment, or the potential value of any investment or informational source. The reader bears responsibility for his/her own investment research and decisions, should seek the advice of a qualified securities professional before making any investment, and investigate and fully understand any and all risks before investing. Millionaire Media LLC and Timothy Sykes in no way warrants the solvency, financial condition, or investment advisability of any of the securities mentioned in communications or websites. In addition, Millionaire Media LLC and Timothy Sykes accepts no liability whatsoever for any direct or consequential loss arising from any use of this information. This information is not intended to be used as the sole basis of any investment decision, nor should it be construed as advice designed to meet the investment needs of any particular investor. Past performance is not necessarily indicative of future returns.

Citations for Disclaimer

Barber, Brad M. and Odean, Terrance, Trading is Hazardous to Your Wealth: The Common Stock Investment Performance of Individual Investors. Available at SSRN: “Day Trading for a Living?”

Barber, Brad M. and Lee, Yi-Tsung and Liu, Yu-Jane and Odean, Terrance and Zhang, Ke, Learning Fast or Slow? (May 28, 2019). Forthcoming: Review of Asset Pricing Studies, Available at SSRN: “https://ssrn.com/abstract=2535636”

Chague, Fernando and De-Losso, Rodrigo and Giovannetti, Bruno, Day Trading for a Living? (June 11, 2020). Available at SSRN: “https://ssrn.com/abstract=3423101”